FOXBOROUGH, Mass .– (COMMERCIAL THREAD) – Suono Bio, Inc., the company that is revolutionizing the treatment of gastrointestinal disease, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the ability to deliver unformulated RNA-based therapies against relevant pathologic targets in the gastrointestinal tract.
This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low frequency ultrasound for formulation independent delivery. This technology was originally developed in the laboratory of Professor Robert Langer Institute at MIT to facilitate the rapid local administration of therapeutics to treat serious illnesses.
“Therapeutic translation of oligos has been hampered by delivery and bioavailability issues with a complicated landscape for chemical-based formulations. This further demonstrates our ability to deliver RNAs and siRNAs to eliminate relevant genetic targets without the need for any formulation. Said Dr Carl Schoellhammer, corresponding author and co-founder of Suono Bio.
In addition to previously demonstrating the preclinical use of siRNAs for the treatment of inflammatory conditions, this latest publication demonstrates the ability to neutralize endogenous genes, including Ctnnb1, the gene encoding beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. The publication can be read for free here: https://authors.elsevier.com/a/1eI4m_WXzjcf9
ABOUT SUONO BIO
Suono Bio was founded by Robert Langer and Giovanni Traverso, gastroenterologist and biomedical engineer in the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr Carl Schoellhammer. The company develops therapeutics for inflammatory-mediated diseases by leveraging their ultra-rapid, formulation-independent delivery technology. Suono Bio’s platform enables rapid and localized delivery of small molecules, biologics, nucleic acids and gene therapies without the need to encapsulate therapeutics. For more information, please visit www.suonobio.com.